News for Healthier Living

Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome

Monell Center investigators identified that GLP-1R agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments. They used a genetically engineered mouse model of BBS that displayed the hallmark features of the condition.

April 17, 2025


April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025